FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center.


Creative Commons License

Bengoa S. Y., Ataseven E., Kizmazoglu D., Yenigurbuz F. D., Erdem M., ÖREN H.

Turkish journal of haematology : official journal of Turkish Society of Haematology, vol.34, no.1, pp.46-51, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.4274/tjh.2015.0411
  • Journal Name: Turkish journal of haematology : official journal of Turkish Society of Haematology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.46-51
  • Keywords: Relapsed/refractory leukemia, FLAG regimen, Chemotherapy, Childhood, ACUTE MYELOGENOUS LEUKEMIA, COLONY-STIMULATING FACTOR, ACUTE MYELOID-LEUKEMIA, RELAPSED ACUTE-LEUKEMIA, HIGH-DOSE CYTARABINE, G-CSF, RANDOMIZED-TRIAL, FLUDARABINE, CHILDHOOD, THERAPY
  • Dokuz Eylül University Affiliated: Yes

Abstract

Objective: The optimal therapy to achieve higher rates of survival in pediatric relapsed/refractory acute leukemia (AL) is still unknown. In developing countries, it is difficult to obtain some of the recent drugs for optimal therapy and mostly well-known drugs proven to be effective are used. We assessed the efficacy of the combination of fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG regimen) with or without idarubicin (IDA) in children with relapsed/refractory acute lymphoblastic leukemia and acute myeloid leukemia.